Unleashing the immune response against childhood solid cancers.
Pediatric Blood & Cancer
pbc26548.pdf - ["content_typename_Accepted version" not defined]
Restricted to Access restricted
Tumor immunotherapy has come to the fore fuelled by impressive clinical responses to checkpoint inhibitor antibodies in a range of adult malignancies and by the success of chimeric antigen receptor T cells targeting adult and pediatric B-cell malignancies. Clearly, if appropriately fine-tuned, the immune system has the capability to seek out and destroy cancer. Studies in pediatric solid cancers so far have not shown the therapeutic potential checkpoint inhibitors described in adult cancers and this may reflect fewer tumor-associated antigens or different immune evasion mechanisms. One potential approach to overcome these limitations will be to combine interventions to undermine immune evasion mechanisms with engineered T-cell adoptive transfer.
|Title:||Unleashing the immune response against childhood solid cancers|
|Keywords:||Checkpoint inhibitors, childhood solid cancer, chimeric antigen receptor, immunotherapy, pediatric solid cancer|
|UCL classification:||UCL > School of Life and Medical Sciences
UCL > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute of Child Health
Archive Staff Only